Riluzole是FDA批准的第一个用于治疗ALS的药物(纯化学药物,与生物学中的肽毫不相关。),Riluzole并不能治愈ALS或者改善病情,但是可能使患者的生命延长三个月左右。研究显示Riluzole对于bulbar型的ALS病人比对于limb型的ALS病人更加有效。
Riluzole的作用机制可能与调节谷氨酰胺有关。Riluzole具有一定的副作用,需要在医生指导下使用。
参见:
http://www.als.net/treatments/options/optionsarticle.asp?articleid=1659
http://www.alsinfo.com/index.jsp
Riluzole is the first drug to be approved for the treatment of amyotrophic lateral sclerosis (ALS). Riluzole does not cure the disease or improve symptoms, but may extend the survival of patients by approximately three months. Riluzole appears to be more effective in patients with bulbar-onset than for those with limb-onset.
Riluzole is believed to modulate the release of glutamate. Glutamate neuronal damage is one of several theories that have been proposed as a cause of ALS. Glutamate is an excitatory amino acid neurotransmitter. The theory in ALS is that glutamate accumulates in toxic concentrations at synapses and causes neurons to die. The theory is supported by evidence of decreased tissue glutamate levels and decreased glutamate reuptake in ALS. At the same time spinal fluid glutamate levels are increased.
It is recommended to contact your doctor as soon as possible if any side effects are noticed. These include fever, chills, infection, breathing difficulty or shortness of breath.
The recommended dose of riluzole is 50 mg by mouth every twelve hours. A dose-ranging study of riluzole in ALS confirmed this dosage as being the most effective. It is recommended by the manufacturer that riluzole be taken on an empty stomach at least one hour before or two hours after a meal. Take your doses at regular intervals. It is recommended that you do not take double or extra doses if a dose is missed. Riluzole is an FDA approved drug for ALS and may be obtained from a medical doctor.
References:
Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). Kennel P. et al. J Neurol Sci 2000 Nov 1;180(1-2):55-61
[Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis]. Roch-Torreilles I.[Article in French] Therapie 2000 Mar-Apr;55(2):303-12
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. Bensimon G. et al. N Engl J Med 1994 Mar 3;330(9):585-91
A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Lacomblez L. et al. Neurology 1996 Dec;47(6 Suppl 4):S242-50
Blood oxidative stress in amyotrophic lateral sclerosis. Bonnefont-Rousselot D. et al. J Neurol Sci 2000 Sep 1;178(1):57-62
For more information, please contact Mary Beth Parks, RN, Patient Services Specialist at mbparks@als.net.
[此贴子已经被作者于2004-4-22 14:36:11编辑过]